194 related articles for article (PubMed ID: 26092968)
21. Associations of the dopamine D4 receptor gene VNTR polymorphism with drug use in adolescent psychiatric inpatients.
McGeary JE; Esposito-Smythers C; Spirito A; Monti PM
Pharmacol Biochem Behav; 2007 Feb; 86(2):401-6. PubMed ID: 17175015
[TBL] [Abstract][Full Text] [Related]
22. Dopaminergic genetic variation moderates the effect of nicotine on cigarette reward.
Harrell PT; Lin HY; Park JY; Blank MD; Drobes DJ; Evans DE
Psychopharmacology (Berl); 2016 Jan; 233(2):351-60. PubMed ID: 26497691
[TBL] [Abstract][Full Text] [Related]
23. Dual growth of adolescent smoking and drinking: evidence for an interaction between the mu-opioid receptor (OPRM1) A118G polymorphism and sex.
Kleinjan M; Poelen EA; Engels RC; Verhagen M
Addict Biol; 2013 Nov; 18(6):1003-12. PubMed ID: 22260295
[TBL] [Abstract][Full Text] [Related]
24. Alcohol Consumption in Healthy OPRM1 G Allele Carriers and Its Association with Impulsive Behavior.
Pfeifer P; Sariyar M; Eggermann T; Zerres K; Vernaleken I; Tüscher O; Fehr C
Alcohol Alcohol; 2015 Jul; 50(4):379-84. PubMed ID: 25836994
[TBL] [Abstract][Full Text] [Related]
25. OPRM1 Moderates Daily Associations of Naltrexone Adherence With Alcohol Consumption: Preliminary Evidence From a Mobile Health Trial.
Hendershot CS; Dermody SS; Wardell JD; Zaso MJ; Kennedy JL; Stoner SA
Alcohol Clin Exp Res; 2020 Apr; 44(4):983-991. PubMed ID: 32020635
[TBL] [Abstract][Full Text] [Related]
26. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial.
Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP
Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383
[TBL] [Abstract][Full Text] [Related]
27. Independent and Interactive Effects of OPRM1 and DAT1 Polymorphisms on Alcohol Consumption and Subjective Responses in Social Drinkers.
Weerts EM; Wand GS; Maher B; Xu X; Stephens MA; Yang X; McCaul ME
Alcohol Clin Exp Res; 2017 Jun; 41(6):1093-1104. PubMed ID: 28376280
[TBL] [Abstract][Full Text] [Related]
28. Naltrexone and alcohol effects on craving for cigarettes in heavy drinking smokers.
Green R; Bujarski S; Lim AC; Venegas A; Ray LA
Exp Clin Psychopharmacol; 2019 Jun; 27(3):257-264. PubMed ID: 30628813
[TBL] [Abstract][Full Text] [Related]
29. Effect of model choice in genetic association studies: DRD4 exon III VNTR and cigarette use in young adults.
Das D; Tan X; Easteal S
Am J Med Genet B Neuropsychiatr Genet; 2011 Apr; 156B(3):346-51. PubMed ID: 21438142
[TBL] [Abstract][Full Text] [Related]
30. Association of µ-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis.
Chamorro AJ; Marcos M; Mirón-Canelo JA; Pastor I; González-Sarmiento R; Laso FJ
Addict Biol; 2012 May; 17(3):505-12. PubMed ID: 22515274
[TBL] [Abstract][Full Text] [Related]
31. The DRD4 VNTR polymorphism moderates craving after alcohol consumption.
Hutchison KE; McGeary J; Smolen A; Bryan A; Swift RM
Health Psychol; 2002 Mar; 21(2):139-46. PubMed ID: 11950104
[TBL] [Abstract][Full Text] [Related]
32. Distress Tolerance and Craving for Cigarettes Among Heavy Drinking Smokers.
Lim AC; Roche DJO; Ray LA
J Stud Alcohol Drugs; 2018 Nov; 79(6):918-928. PubMed ID: 30573023
[TBL] [Abstract][Full Text] [Related]
33. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction.
Hutchison KE; Wooden A; Swift RM; Smolen A; McGeary J; Adler L; Paris L
Neuropsychopharmacology; 2003 Oct; 28(10):1882-8. PubMed ID: 12888781
[TBL] [Abstract][Full Text] [Related]
34. Topiramate versus naltrexone for alcohol use disorder: study protocol for a genotype-stratified, double-blind randomised controlled trial (TOP study).
Morley KC; Kranzler HR; Luquin N; Baillie A; Shanahan M; Trent R; Teesson M; Haber PS
Trials; 2018 Aug; 19(1):443. PubMed ID: 30115121
[TBL] [Abstract][Full Text] [Related]
35. OPRM1 A118G genotype fails to predict the effectiveness of naltrexone treatment for alcohol dependence.
Coller JK; Cahill S; Edmonds C; Farquharson AL; Longo M; Minniti R; Sullivan T; Somogyi AA; White JM
Pharmacogenet Genomics; 2011 Dec; 21(12):902-5. PubMed ID: 21946895
[TBL] [Abstract][Full Text] [Related]
36. Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.
Oslin DW; Leong SH; Lynch KG; Berrettini W; O'Brien CP; Gordon AJ; Rukstalis M
JAMA Psychiatry; 2015 May; 72(5):430-7. PubMed ID: 25760804
[TBL] [Abstract][Full Text] [Related]
37. Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Morley KC; Kranzler HR; Luquin N; Jamshidi N; Adams C; Montebello M; Tremonti C; Dali G; Logge W; Baillie A; Teesson M; Trent R; Haber PS
Am J Psychiatry; 2024 May; 181(5):403-411. PubMed ID: 38706338
[TBL] [Abstract][Full Text] [Related]
38. A pharmacogenetic model of naltrexone-induced attenuation of alcohol consumption in rhesus monkeys.
Vallender EJ; Rüedi-Bettschen D; Miller GM; Platt DM
Drug Alcohol Depend; 2010 Jun; 109(1-3):252-6. PubMed ID: 20153935
[TBL] [Abstract][Full Text] [Related]
39. Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.
Ray LA; Bujarski S; Chin PF; Miotto K
Neuropsychopharmacology; 2012 Jan; 37(2):445-55. PubMed ID: 21900886
[TBL] [Abstract][Full Text] [Related]
40. Interactive effects of OPRM1 and DAT1 genetic variation on subjective responses to alcohol.
Ray LA; Bujarski S; Squeglia LM; Ashenhurst JR; Anton RF
Alcohol Alcohol; 2014; 49(3):261-70. PubMed ID: 24421289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
